0D1W Stock Overview

A clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. More details

0D1W fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Rewards

Earnings have grown 2.6% per year over the past 5 years

Risk Analysis

Highly volatile share price over the past 3 months compared to the UK market

Negative shareholders equity

Makes less than USD$1m in revenue (€0)

Shareholders have been substantially diluted in the past year

+ 2 more risks

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Biophytis S.A. Competitors

Roquefort Therapeutics

LSE:ROQ

UK£2.5m

ValiRx

AIM:VAL

UK£2.0m

BSF Enterprise

LSE:BSFA

UK£3.2m

Verici Dx

AIM:VRCI

UK£3.3m

Price History & Performance

Summary of share price highs, lows and changes for Biophytis
Historical stock prices
Current Share Price	€0.16
52 Week High	€1.35
52 Week Low	€0.14
Beta	0.25
1 Month Change	-7.53%
3 Month Change	-49.66%
1 Year Change	-78.95%
3 Year Change	-99.71%
5 Year Change	-99.97%
Change since IPO	-99.99%

Recent updates

Shareholder Returns

	0D1W	GB Biotechs	GB Market
7D	1.2%	-2.5%	0.2%
1Y	-78.9%	-14.9%	-0.07%

Return vs Industry: 0D1W underperformed the UK Biotechs industry which returned -13.2% over the past year.

Return vs Market: 0D1W underperformed the UK Market which returned 0.1% over the past year.

Price Volatility

Is 0D1W's price volatile compared to industry and market?
0D1W volatility
0D1W Average Weekly Movement	12.9%
Biotechs Industry Average Movement	9.2%
Market Average Movement	5.8%
10% most volatile stocks in GB Market	11.3%
10% least volatile stocks in GB Market	3.2%

Stable Share Price: 0D1W's share price has been volatile over the past 3 months compared to the UK market.

Volatility Over Time: 0D1W's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of UK stocks.

About the Company

Founded	Employees	CEO	Website
2006	22	Stanislas Veillet	www.biophytis.com

Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics targets and activates key biological resilience pathways that can protect against and counteract the effects of the multiple biological and environmental stresses, including inflammatory, oxidative, metabolic, and viral stresses that lead to age-related diseases. The company’s lead drug candidate is BIO101, an orally administered small molecule in development to treat neuromuscular diseases, including sarcopenia, Duchenne muscular dystrophy (DMD), and obesity, as well as treatment of severe respiratory failure in patients suffering from COVID-19.

Biophytis S.A. Fundamentals Summary

How do Biophytis's earnings and revenue compare to its market cap?
0D1W fundamental statistics
Market cap	€3.24m
Earnings (TTM)	-€15.07m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-0.2x

P/E Ratio

Is 0D1W overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0D1W income statement (TTM)
Revenue	€0
Cost of Revenue	€0
Gross Profit	€0
Other Expenses	€15.07m
Earnings	-€15.07m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.75
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	-148.8%

How did 0D1W perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/05/13 01:19
End of Day Share Price	2025/05/13 00:00
Earnings	2024/06/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Biophytis S.A. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Raghuram Selvaraju	H.C. Wainwright & Co.
Joseph Pantginis	H.C. Wainwright & Co.
Thomas Guillot	Kepler Cheuvreux

0D1W Stock Overview

Rewards

Risk Analysis

Biophytis S.A. Competitors

LSE:ROQ

UK£2.5m

AIM:VAL

UK£2.0m

LSE:BSFA

UK£3.2m

AIM:VRCI

UK£3.3m

Price History & Performance

Recent News & Updates

Biophytis S.A. announced delayed 20-F filing

Biophytis S.A. Confirms the Launch of the Phase 2 Oba Clinical Trial in Obesity

Biophytis SA Obtains IND Approval from the FDA to Start Its Phase 2 Oba Study in Obesity

Biophytis S.A., Annual General Meeting, Jun 24, 2024

Biophytis SA Announces the Design of its Phase 2 OBA Clinical Study in Obesity

Biophytis S.A.(OTCPK:BPTS.Y) dropped from NASDAQ Composite Index

Recent updates

Biophytis S.A. announced delayed 20-F filing

Biophytis S.A. Confirms the Launch of the Phase 2 Oba Clinical Trial in Obesity

Biophytis SA Obtains IND Approval from the FDA to Start Its Phase 2 Oba Study in Obesity

Biophytis S.A., Annual General Meeting, Jun 24, 2024

Biophytis SA Announces the Design of its Phase 2 OBA Clinical Study in Obesity

Biophytis S.A.(OTCPK:BPTS.Y) dropped from NASDAQ Composite Index

Biophytis SA Announces Formation of New Scientific Advisory Board for Its Phase 2 OBA Clinical Study in Obesity

Biophytis SA Launches OBA Phase 2 Clinical Study in Obesity with BIO101 (20-Hydroxyecdysone)

Biophytis S.A., Annual General Meeting, Mar 18, 2024

Biophytis S.A. Announces the Publication of the Results of its COVA Phase 2-3 Study in eClinicalMedicine, Part of The Lancet

Biophytis S.A. and the University of Li Ge Explore the Potential of Sarconeos (BIO101) in the Treatment of Viral Respiratory Diseases

Biophytis S.A. Appoints Yann Meunier and Bernard L vy to its Scientific Advisory Board

Biophytis Receives Notice of Delisting from Nasdaq and Announces It Will Request A Hearing Before the Nasdaq Hearings Panel

Biophytis S.A. Provides an Update on the Progress of its R&D Projects over the 1St Half of the Year and the Last Few Months

Biophytis SA Provides Update on its Early Access Programs for Sarconeos (BIO101) in Treatment of Severe Forms of COVID-19

Biophytis SA Receives Response from the French National Authority for Health to Request for Early Access Authorization in France for Patients Suffering from Severe Forms of COVID-19

Biophytis S.A. Announces Executive Changes

Biophytis Obtains Fda Authorization to Initiate the Sara-31 Phase 3 Study in Sarcopenia

Biophytis SA Announces Next Regulatory Steps in Europe and the United States for its COVA Project

Biophytis SA Receives Positive Opinion for its SARA-31 Phase 3 Study in Sarcopenia in Europe

Biophytis S.A. Files for a Pre-Submission Meeting with the FDA for an Emergency Use Authorization of Sarconeos (BIO101) for the Treatment of COVID-19

Biophytis and Seqens Sign A Partnership to Produce Sarconeos (Bio101) Active Compound

Biophytis SA Filed with the FDA for Authorization to Initiate SARA-31 Phase 3 Study in Sarcopenia

Biophytis SA Reports Clinical Results for Sarconeos (BIO101) in Sarcopenia Treatment at the 16th SCWD International Congress

Biophytis S.A., Annual General Meeting, Jun 16, 2023

Biophytis S.A. has completed a Follow-on Equity Offering in the amount of €2.302535 million.

Biophytis SA Files for Pre-Submission Meeting Request with the European Medicine Agency (EMA) to Discuss Filing for Conditional Marketing Authorisation (CMA) in Europe

Biophytis Announces Positive Final Results of the Phase 2-3 COVA Study with Sarconeos (BIO101) in Severe COVID-19

Biophytis S.A. Judgment of the Paris Court of Appeal of 17 January 2023 in the Case Between Biophytis and Negma Group Ltd

Biophytis to Take Appropriate Measures After Receiving Nasdaq Deficiency Notice

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Shareholder Returns

Price Volatility

About the Company

Biophytis S.A. Fundamentals Summary

0.0x

-0.2x

Earnings & Revenue

Company Analysis and Financial Data Status

Data Sources

Analysis Model and Snowflake

Industry and Sector Metrics

Analyst Sources